Repertoire will obtain an upfront payment of $35m from Genentech, with the potential for up to $730m in additional milestones ...

Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T ...

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted medicines in the autoimmune disease space. Flagship Pioneering-backed ...

Repertoire Immune Medicines has formed its second pharmaceutical partnership since changing course a few years ago, announcing Wednesday a new deal with Roche’s Genentech division to develop ...

Genentech caved to President Trump's anti-DEI push. Now Roche is trying to get ahead of Trump's pressure, including with tariffs, to invest in the United States. Where big pharma fails ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

The test enables earlier identification of patients with significant liver fibrosis, potentially improving outcomes through timely management and access to emerging therapies.

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low tumor burden follicular lymphoma can substantially delay the need for further ...